Fig. 1
From: XPO1-mutant NSCLC without STK11/KEAP1 mutations may predict better survival to immunotherapy
The prognostic value of XPO1 mutations in NSCLC patients with immune checkpoint inhibitors. A Kaplan–Meier curve comparing OS of NSCLC patients with XPO1 mutations and their wild type counterparts. B Kaplan–Meier curve comparing OS of NSCLC patients with pure XPO1 mutations, wild type and comutation of STK11/KEAP1 with XPO1 mutations. OS, overall survival; NSCLC, non-small-cell lung cancer